Iron Pillar

Vyome is an innovation-driven, clinical stage specialty pharmaceutical company

Mumbai—Iron Pillar, a venture growth investor with a presence in Mumbai and Palo Alto, is pleased to announce an investment in Vyome (Vyome Therapeutics Inc.), a clinical stage company developing novel drugs for antibiotic-resistant acne and other dermatology applications. This is Iron Pillar’s fifth investment from its maiden fund. Iron Pillar led the $22 million Series D round, which also saw investments from other new investors. Existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated in this raise. Part of the funds are being used for a secondary transaction.

Vyome’s management team members are leaders in the field, with deep expertise and a proven track record of successfully launching over 50 products in dermatology and other life sciences areas, and building visionary companies. Vyome has leveraged a combination of high-end computational biology, genomic analysis and proprietary chemistry to build a robust pipeline of patent-protected products targeting multiple dermatology indications. The lead molecule, VB 1953, which targets the large unmet need in the antibiotics-resistant acne prescription market, is currently being evaluated in advanced stage clinical trials in the U.S. Vyome has recently signed an out-licensing deal of marketing rights with a large specialty pharma company around its patented Molecular Replacement Therapeutics (MRT™) platform for treatment of resistant fungal diseases of skin.

Venkateswarlu (Venkat) Nelabhotla, CEO of Vyome, said “Vyome’s Series D raise comes at a transformational time for the company, as we prepare to initiate a phase 2b clinical trial with our lead candidate, VB 1953, and as we establish the center of operations in the U.S. We see this financing led by Iron Pillar as validation of Vyome’s innovative approach to efficient specialty pharmaceutical development and the ability of the company’s platform technologies to help solve the problem of microbial resistance related to skin pathogens. Establishing a U.S. company with access to U.S. capital markets and a robust talent pool, will allow us to push our programs forward with precision and efficiency.”

Mohanjit Jolly, Partner at Iron Pillar, added “We are thrilled to partner with Vyome and cement our long-standing relationship with co-founders Shiladitya and Venkat. This investment fits well with Iron Pillar’s approach of backing visionary entrepreneurs who are driving world-class innovation along with proven execution. Vyome is a unique U.S.-India play addressing a large unmet need with products that can leapfrog the competition. We look forward to leveraging our cross-border network and our U.S. capital markets experience to support Vyome as it seeks to establish itself as a leading life sciences technology company.”

About Vyome Therapeutics

Vyome Therapeutics is a clinical stage specialty pharmaceutical company, developing a deep pipeline of novel drugs for treatment of drug-resistant skin pathogens, including antibiotics-resistant P. acnes. The company’s lead drug candidate, VB 1953, will enter phase 2b clinical trial in the first quarter of 2019.  VB 1953 is a topical treatment for antibiotic-resistant acne, which is currently an emerging and unmet need with a potential $2 billion market opportunity in the U.S. alone. Vyome has a deep pipeline of preclinical new chemical entities, based on its patented Dual Action Rational Therapeutics (DARTs) technology, which are unique in their ability to overcome antimicrobial resistance. Vyome has developed clinically-validated antifungal products based on its innovative and patented technology platform Molecular Replacement Therapeutics (MRT™), a platform for which Vyome has recently signed an out-licensing deal of marketing rights with a large specialty pharma company. Vyome has assembled a world-class team of scientific and business development experts who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. Additional information is available at

Media Contact

For Iron Pillar, Sanjna Tulsiani: [email protected]

Download Press Release

About Iron Pillar

Iron Pillar

Iron Pillar is a venture growth investor specializing in mid stage technology companies “Built from India”. Founded in January 2016, Iron Pillar provides growth capital and active help in global business expansion to companies in the enterprise and consumer technology sectors. The Fund backs founding teams who want to create $1B+ enterprise value companies that are built to last. Additional information on Iron Pillar is available at